Emerging Predictors by Non-HDL-C/HDL-C Ratio and Novel Biomarkers for Coronary Slow Flow Phenomenon.

IF 1.8 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Acta Cardiologica Sinica Pub Date : 2024-07-01 DOI:10.6515/ACS.202407_40(4).20240624A

Tharmaraj Vairaperumal, Zong-Yun Tsai, Ping-Yen Liu

{"title":"Emerging Predictors by Non-HDL-C/HDL-C Ratio and Novel Biomarkers for Coronary Slow Flow Phenomenon.","authors":"Tharmaraj Vairaperumal, Zong-Yun Tsai, Ping-Yen Liu","doi":"10.6515/ACS.202407_40(4).20240624A","DOIUrl":null,"url":null,"abstract":"<p><p>The coronary slow-flow (CSF) phenomenon is a condition characterized by delayed coronary opacification during diagnostic angiography without the presence of epicardial coronary artery disease. This mini-review explores various emerging predictors and biomarkers associated with CSF, aiming to address the potential diagnostic tools. A comprehensive analysis of recent studies has investigated different biomarkers, including growth differentiation factor 15, galectin 3, microRNA (miRNA)-22, miRNA-155, interleukin 34, soluble vascular cell adhesion molecule-1, long non-coding RNA, plasma choline, adropin, and lipid markers non-high-density lipoprotein cholesterol (HDL-C)/HDL-C ratio to enhance understanding and predict CSF. Additionally, we have summarizes the major findings and significant limitations observed in various studies on CSF biomarkers. The implications of these findings suggest significant advancements in personalized treatment strategies and improved prognostic outcomes for patients exhibiting CSF.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"40 4","pages":"367-372"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11261357/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cardiologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6515/ACS.202407_40(4).20240624A","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The coronary slow-flow (CSF) phenomenon is a condition characterized by delayed coronary opacification during diagnostic angiography without the presence of epicardial coronary artery disease. This mini-review explores various emerging predictors and biomarkers associated with CSF, aiming to address the potential diagnostic tools. A comprehensive analysis of recent studies has investigated different biomarkers, including growth differentiation factor 15, galectin 3, microRNA (miRNA)-22, miRNA-155, interleukin 34, soluble vascular cell adhesion molecule-1, long non-coding RNA, plasma choline, adropin, and lipid markers non-high-density lipoprotein cholesterol (HDL-C)/HDL-C ratio to enhance understanding and predict CSF. Additionally, we have summarizes the major findings and significant limitations observed in various studies on CSF biomarkers. The implications of these findings suggest significant advancements in personalized treatment strategies and improved prognostic outcomes for patients exhibiting CSF.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

通过非高密度脂蛋白胆固醇/高密度脂蛋白胆固醇比率和新型生物标记物预测冠状动脉慢流现象的新方法

冠状动脉慢血流（CSF）现象是一种在诊断性血管造影中冠状动脉延迟不透明而又不存在心外膜冠状动脉疾病的情况。这篇微型综述探讨了与 CSF 相关的各种新兴预测指标和生物标志物，旨在解决潜在的诊断工具问题。通过对近期研究的全面分析，我们研究了不同的生物标志物，包括生长分化因子 15、galectin 3、microRNA (miRNA)-22、miRNA-155、白细胞介素 34、可溶性血管细胞粘附分子-1、长非编码 RNA、血浆胆碱、阿糖腺苷和血脂标志物非高密度脂蛋白胆固醇 (HDL-C)/HDL-C 比值，以加深理解并预测 CSF。此外，我们还总结了有关 CSF 生物标志物的各种研究的主要发现和重大局限性。这些发现的影响表明，个性化治疗策略取得了重大进展，并改善了 CSF 患者的预后结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Acta Cardiologica Sinica 医学-心血管系统

CiteScore

2.90

自引率

15.80%

发文量

144

审稿时长

>12 weeks

期刊介绍： Acta Cardiologica Sinica welcomes all the papers in the fields related to cardiovascular medicine including basic research, vascular biology, clinical pharmacology, clinical trial, critical care medicine, coronary artery disease, interventional cardiology, arrythmia and electrophysiology, atherosclerosis, hypertension, cardiomyopathy and heart failure, valvular and structure cardiac disease, pediatric cardiology, cardiovascular surgery, and so on. We received papers from more than 20 countries and areas of the world. Currently, 40% of the papers were submitted to Acta Cardiologica Sinica from Taiwan, 20% from China, and 20% from the other countries and areas in the world. The acceptance rate for publication was around 50% in general.